Anti-EBV Latent Membrane Protein 1 antibody [CS 1-4] (ab78113)
Key features and details
- Mouse monoclonal [CS 1-4] to EBV Latent Membrane Protein 1
- Suitable for: WB, IP, IHC-P, IHC-Fr
- Isotype: IgG1
Overview
-
Product name
Anti-EBV Latent Membrane Protein 1 antibody [CS 1-4]
See all EBV Latent Membrane Protein 1 primary antibodies -
Description
Mouse monoclonal [CS 1-4] to EBV Latent Membrane Protein 1 -
Host species
Mouse -
Specificity
This antibody is specific for Epstein-Barr virus infected cells expressing the latent membrane protein (LMP). This is in fact four pooled antibodies which collectively detect LMP's encoded by each of 20 geographically distinct EBV isolates. -
Tested applications
Suitable for: WB, IP, IHC-P, IHC-Frmore details -
Species reactivity
Reacts with: Epstein-Barr virus -
Immunogen
Fusion protein corresponding to EBV Latent Membrane Protein 1.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
Storage buffer
Constituent: PBS -
Concentration information loading... -
Purity
Protein A/G purified -
Clonality
Monoclonal -
Clone number
CS 1-4 -
Myeloma
x63-Ag8.653 -
Isotype
IgG1 -
Light chain type
kappa -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab78113 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB | (2) |
Use at an assay dependent concentration. Predicted molecular weight: 57-66 kDa.
|
| IP |
Use at an assay dependent concentration.
|
|
| IHC-P |
Use at an assay dependent concentration.
|
|
| IHC-Fr |
Use at an assay dependent concentration.
|
| Notes |
|---|
|
WB
Use at an assay dependent concentration. Predicted molecular weight: 57-66 kDa. |
|
IP
Use at an assay dependent concentration. |
|
IHC-P
Use at an assay dependent concentration. |
|
IHC-Fr
Use at an assay dependent concentration. |
Target
-
Relevance
EBV is a human herpesvirus that establishes a life-long persistence in the host. The virus infects the vast majority of the world's adult population and is well known for its association with a broad spectrum of benign and malignant diseases, including infectious mononucleosis, Burkitt's lymphoma, nasopharyngeal carcinoma, and is causally associated with lymphoid and epithelial malignancies, including post-transplant lymphoproliferative disorders, Hodgkin's disease, anaplastic nasopharyngeal carcinoma and gastric carcinomas. Latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) is a transforming protein that affects multiple cell signalling pathways and contributes to EBV-associated oncogenesis. LMP1 can be expressed in some states of EBV latency, and significant induction of full-length LMP1 is also observed frequently during virus reactivation into the lytic cycle. LMP1 is critical for EBV-infected cell activation, adhesion and survival, and is usually expressed in the malignant cells. -
Database links
- Entrez Gene: 3783750 Epstein-Barr virus
- SwissProt: P0C741 Epstein-Barr virus
-
Alternative names
- BNLF1 antibody
- EBV antibody
- Epstein Barr virus antibody
see all
Protocols
References (24)
ab78113 has been referenced in 24 publications.
- Ye D et al. LMP1 Up-regulates Calreticulin to Induce Epithelial-mesenchymal Transition via TGF-ß/Smad3/NRP1 Pathway in Nasopharyngeal Carcinoma Cells. J Cancer 11:1257-1269 (2020). PubMed: 31956372
- Shi F et al. Wild-type IDH2 contributes to Epstein-Barr virus-dependent metabolic alterations and tumorigenesis. Mol Metab 36:100966 (2020). PubMed: 32224436
- Wang ZH et al. CD47 Overexpression Is Associated with Epstein-Barr Virus Infection and Poor Prognosis in Patients with Nasopharyngeal Carcinoma. Onco Targets Ther 13:3325-3334 (2020). PubMed: 32368091
- Gu J et al. Matrine inhibits the growth of natural killer/T-cell lymphoma cells by modulating CaMKII?-c-Myc signaling pathway. BMC Complement Med Ther 20:214 (2020). PubMed: 32641029
- Shi F et al. EBV(LMP1)-induced metabolic reprogramming inhibits necroptosis through the hypermethylation of the RIP3 promoter. Theranostics 9:2424-2438 (2019). PubMed: 31131045
